Credo CFO Reports 112,580-Share Sale Under 10b5-1 Plan
Rhea-AI Filing Summary
The Chief Financial Officer, Daniel W. Fleming, reported three open-market sales of Credo Technology Group Holding Ltd (CRDO) stock executed on 10/08/2025 under a Rule 10b5-1 trading plan adopted on 06/19/2025. The filings show a total of 112,580 ordinary shares sold in multiple executions at weighted average prices of $137.8361, $138.6003, and $139.4195, reducing reported beneficial holdings sequentially to 507,082, 463,196, and 458,678 shares after each sale. The Form 4 is signed by an attorney-in-fact and includes explanations that each reported price is a weighted average of multiple trade prices and that full trade details will be provided upon request.
Positive
- Sales executed under a documented Rule 10b5-1 plan, which provides an affirmative defense and transparency about intent
- Weighted average prices disclosed with explicit ranges and an offer to provide full trade details on request
Negative
- Total insider sales of 112,580 shares on 10/08/2025 reduced reported beneficial ownership to 458,678 shares
- Multiple sequential reductions in holdings (to 507,082, then 463,196, then 458,678), which materially lower the CFO's reported stake
Insights
CFO executed planned, multiple open-market sales under a Rule 10b5-1 plan.
The report documents that Daniel W. Fleming used a Rule 10b5-1 plan adopted on 06/19/2025 to sell a total of 112,580 ordinary shares on 10/08/2025. The 10b5-1 plan disclosure signals the sales were pre-arranged and intended to provide an affirmative defense to insider trading claims.
Continued reliance on a documented trading plan reduces governance concern over opportunistic timing but investors may monitor subsequent Form 4 filings to see whether planned sales materially change executive ownership over the next 6–12 months.
Sales executed in multiple trades with weighted average prices disclosed; detailed trade breakdown available on request.
The Form 4 reports three separate sale groupings with weighted average prices of $137.8361, $138.6003, and $139.4195, and discloses that individual trade prices ranged within specified brackets. The filer affirms willingness to provide full execution details to regulators or security holders.
Compliance teams and investors can request the per-trade data for precise trade timing analysis; any material deviation from planned parameters would surface in follow-up filings or voluntary disclosures within weeks.
FAQ
What did CRDO CFO Daniel W. Fleming sell on the Form 4 filed 10/10/2025?
At what prices were the CRDO shares sold by the CFO?
Was the sale part of a pre-arranged trading plan?
How much did the CFO own after the reported transactions?
Can investors obtain the per-trade execution details?